Loading...
Loading...
Sarepta Therapeutics, Inc.
, a developer of innovative RNA-based
therapeutics, today announced positive safety results from a Phase I multiple
ascending dose study of AVI-7288 in healthy volunteers. AVI-7288, which uses
Sarepta's advanced and proprietary PMOplus™ chemistry, is the company's lead
drug candidate for the treatment of Marburg virus infection. Sarepta has been
developing AVI-7288 under a Department of Defense contract managed by the
Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint
Product Management Office.
The Phase I clinical study was a randomized, double-blind, placebo-controlled
trial that enrolled 40 healthy adult volunteers, and was designed to
characterize the safety, tolerability and pharmacokinetics of AVI-7288 after
daily repeat dosing. In each of five cohorts, six subjects received AVI-7288
and two subjects received placebo, daily for 14 days. Results showed that
AVI-7288 was well tolerated through the highest dose tested, 16 mg/kg per day,
which is higher than the anticipated therapeutic dose, with no reported
serious or clinically significant adverse events. An independent Data and
Safety Monitoring Board reviewed blinded safety results from the study and
recommended continued clinical development of AVI-7288.
“We are very encouraged by the AVI-7288 study results announced today,” said
Chris Garabedian, president and chief executive officer of Sarepta
Therapeutics. “These safety data, combined with previously reported efficacy
results showing up to 100 percent survival in infected animals, differentiates
AVI-7288 as the most advanced medical countermeasure in development for the
treatment of Marburg infection.”
"The new data for AVI-7288 add to a growing body of evidence supporting the
safety and activity of Sarepta's PMO-based chemistries,” said Art Krieg, M.D.,
senior vice president and chief scientific officer of Sarepta Therapeutics.
“Our proprietary RNA technologies offer a versatile drug development platform
with broad potential utility across a spectrum of therapeutic areas.”
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in